Clinical Research Progress of L-carnitine in the Treatment of Primary Carnitine Deficiency
10.3870/j.issn.1004-0781.2024.03.013
- VernacularTitle:左旋肉碱治疗原发性肉碱缺乏症的临床研究进展
- Author:
Xian LI
1
;
Fei YU
Author Information
1. 湖北医药学院湖北省妇幼保健院培养基地,武汉 430070
- Keywords:
L-carnitine;
Primary carnitine deficiency;
Trimethylamine N-oxide
- From:
Herald of Medicine
2024;43(3):402-407
- CountryChina
- Language:Chinese
-
Abstract:
L-carnitine is a carrier that assist in transport of long-chain fatty acids into mitochondria and an effective drug for treating primary carnitine deficiency(PCD).Starting supplementation as early as possible before irreversible organ damage oc-cured can alleviate organ damage,reduce the risk of sudden death,and improve the quality of life.However,in recent years,some studies have suggested that long-term oral L-carnitine has potential risks,the metabolism of L-carnitine through intestinal flora re-sults in the production of trimethylamine oxide(TMAO),which can increase the risk of cardiovascular disease(CVD).There-fore,this paper summarizes the clinical research progress of L-carnitine in treating PCD to provide a theoretical basis for the clini-cal application of L-carnitine in PCD.
